Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice

[1] (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.10.1038/nature11252340196622810696Search in Google Scholar

[2] Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.10.1200/JCO.2007.14.711618316791Search in Google Scholar

[3] Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.10.1056/NEJMoa080438518946061Search in Google Scholar

[4] Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, et al. (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034.10.1056/NEJMoa130527524024839Search in Google Scholar

[5] Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, et al. (2013) Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 19: 1902-1912.10.1158/1078-0432.CCR-12-191323325582Search in Google Scholar

[6] Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167.10.1093/emboj/19.13.315931395810880430Search in Google Scholar

[7] Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.10.1158/0008-5472.CAN-06-019116618717Search in Google Scholar

[8] Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, et al. (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as frst-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546.10.1093/annonc/mdq63221228335Search in Google Scholar

[9] Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2010) Randomized, phase III trial of panitumumab with infusional fuorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as frst-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705.10.1200/JCO.2009.27.486020921465Search in Google Scholar

[10] Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, et al. (2011) Cetuximab plus irinotecan, fuorouracil, and leucovorin as frst-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019. Kohne CH, Lenz HJ (2009) Chemotherapy with10.1200/JCO.2010.33.509121502544Search in Google Scholar

[11] targeted agents for the treatment of metastatic colorectal cancer. Oncologist 14: 478-488. Saridaki Z, Georgoulias V, Souglakos J (2010)10.1634/theoncologist.2008-020219411318Search in Google Scholar

[12] Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 16: 1177-1187. Saridaki Z, Papadatos-Pastos D, Tzardi M,10.3748/wjg.v16.i10.1177283916920222160Search in Google Scholar

[13] Mavroudis D, Bairaktari E, et al. (2010) BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome. Br J Cancer 102: 1762-1768. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M,10.1038/sj.bjc.6605694288369820485284Search in Google Scholar

[14] Pega F, et al. (2011) Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 6: e15980. Souglakos J, Philips J, Wang R, Marwah S,10.1371/journal.pone.0015980302432521283802Search in Google Scholar

[15] Silver M, et al. (2009) Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101: 465-472. De Roock W, Claes B, Bernasconi D, De Schutter J,10.1038/sj.bjc.6605164272023219603024Search in Google Scholar

[16] Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B,Search in Google Scholar

[17] Salvatore L, et al. (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101: 715-721. Lurkin I, Stoehr R, Hurst CD, van Tilborg AA,10.1038/sj.bjc.6605177273683119603018Search in Google Scholar

[18] Knowles MA, et al. (2010) Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 5: e8802. Schwartzberg LS, Rivera F, Karthaus M, Fasola G,10.1371/journal.pone.0008802280909920098682Search in Google Scholar

[19] Canon JL, et al. (2014) PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modifed Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. J Clin Oncol. Hacker E, Nagore E, Cerroni L, Woods SL,Search in Google Scholar

[20] Hayward NK, et al. (2013) NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: fndings from Spanish and Austrian populations. J Invest Dermatol 133: 1027-1033. Park SJ, Sun JY, Hong K, Kwak JY, Kim EK, et al.10.1038/jid.2012.38523096702Search in Google Scholar

[21] (2013) Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. Clin Chem Lab Med 51: 1673-1680. Banerji U, Affolter A, Judson I, Marais R, Workman10.1515/cclm-2012-037523585181Search in Google Scholar

[22] P (2008) BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 7: 737-739. Joseph RW, Sullivan RJ, Harrell R,10.1158/1535-7163.MCT-08-014518375819Search in Google Scholar

[23] Stemke-Hale K, Panka D, et al. (2012) Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 35: 66-72.10.1097/CJI.0b013e3182372636324189022130161Search in Google Scholar